The Suppressive Effect of Deoxyspergualin on the Differentiation of Human B Lymphocytes Maturing Into Immunoglobulin-Producing Cells

Deoxyspergualin: A New Immunosuppressive Drug for the Treatment of Auto-Immune Disease

“…Deoxyspergualin directly inhibits IgG production by B cells in response to a challenge by both T-cell-dependent and T-cell-independent antigens [44], While B cell prolif eration is not inhibited by deoxyspergualin, the drug does prevent the differentiation of B cells into antibody-secret- 392 Nikolic-Patcrson/Kerr/Lan/Tesch/Atkins Deoxyspergualin and Auto-Immune Disease Fig. 1.…”

Evaluation of the ameliorative effects of immunosuppressants on crescentic glomerulonephritis in SCG/Kj mice

“…DSG is an analogue of spergualin [6] isolated from culture filtrate of Bacillus laterosporus, and bears a moiety of spermidine and a guanidinic group. DSG has been found to suppress humoral and cell-mediated immune responses [7][8][9][10][11][12][13]. Although the mechanism behind the DSGmediated immunosuppression is still not unraveled, it is known that DSG binds to a member of the heat shock protein 70 family and may inhibit the translocation of nuclear factor NF-κB and the expression of MHC class II antigens [14][15][16][17].…”

Deoxyspergualin, an immunosuppressant, in patients suffering from nephropathies with crescent formation: an open-label trial to evaluate safety and efficacy

“…5 This analogue, bearing a spermidine moiety and a guanidinic group, strongly suppresses not only cell-mediated but also humoral immune responses, [6][7][8][9][10][11][12] and has been proven effective in suppressing acute rejection when administered intravenously (IV) to renal transplant patients in doses of 3 mg/kg to 6 mg/kg for 5 to 10 days. [13][14][15] Moreover, since DSG was effective in various renal disease models of lupus nephritis and crescentic GN, [16][17][18][19][20][21][22] 3 patients suffering from progressive GN with crescents were given a lower IV dose, of 0.25 mg/ kg of DSG, for 4 weeks.…”